219 results about "Long term treatments" patented technology

This invention relates to a method of selectively enhancing the analgesic potency of morphine and other clinically used bimodally-acting opioid agonists and simultaneously attenuating development of physical dependence, tolerance and other undesirable side effects caused by the chronic administration of said bimodally-acting opioid agonists comprising the co-administration of a bimodally-acting opioid agonist which activates both inhibitory and excitatory opioid receptor-mediated functions of neurons in the nociceptive (pain) pathways of the nervous system and an opioid receptor antagonist which selectively inactivates excitatory opioid receptor-mediated side effects. This invention also relates to a method of using excitatory opioid receptor antagonists alone to block the undesirable excitatory side effects of endogenous bimodally-acting opioid agonists which may be markedly elevated during chronic pain. This invention further relates to a method of long-term treatment of previously detoxified opiate, cocaine and alcohol addicts utilizing said excitatory opioid receptor antagonists, either alone or in combination with low-dose methadone, to prevent protracted physical dependence, and to compositions comprising an excitatory opioid receptor antagonist of the invention and a bimodally-acting opioid agonist.

A tinnitus method and device for providing relief to a person suffering from the disturbing effects of tinnitus is described. The method can be implemented entirely in software to spectrally modify an audio signal in accordance with a predetermined masking algorithm which modifies the intensity of the audio signal at selected frequencies. A predetermined masking algorithm is described which provides intermittent masking of the tinnitus wherein, at a comfortable listening level, during peaks of the audio signal the tinnitus is completely obscured, whereas during troughs the perception of the tinnitus occasionally emerges. In practice it has been found that such intermittent masking provides an immediate sense of relief, control and relaxation for the person, whilst enabling sufficient perception of the tinnitus for habituation and long term treatment to occur. Advantageously the predetermined masking algorithm is specifically tailored to the audiometric configuration of the person. For example, the masking algorithm may be partly tailored to the hearing loss characteristic of the person. A tinnitus rehabilitation device used in conjunction with a personal sound reproducing system is also described.

The present invention is related to mammalian nutrition and effects thereof in individuals with age associated cognitive decline such as Age Associated Memory Inpairment (AAMI) or a dementing illness such as Alzheimer's disease or related dementia, or Mild Cognitive Impairment, such as improving performance in, or reversal, prevention, reducing and delaying decline in, one or more of cognitive function, memory, behavior, cerebrovascular function, motor function, and / or brain physiology are seen. In particular, the present invention utilizes medium chain triglycerides, in one embodiment, administered as part of a long-term treatment regimen, to preserve or improve learning, attention, motor performance, cerebrovascular function, social behavior, and to increase activity levels, particularly in aging mammals.

The present invention provides sustained release formulations of estradiol metabolites whereby the in vivo pharmacokinetics are manipulated by a method selected from the group consisting of chemical modification, crystal packing formation, particle size or a combination thereof. Such compositions are useful in the long-term treatment of a wide variety of diseases.

This invention relates to a method and pharmaceutical composition useful in treating a condition responsive to hormone replacement therapy. Specifically, the invention is related to the long term treatment of symptoms associated with atrophic vaginitis. The composition contains effective amounts of an estrogen, a progesterone compound and a pharmaceutically accepted vehicle, carrier and / or diluent.

Disclosed are uses of immunotherapeutic compositions in combination with Standard of Care (SOC), or interferon therapy combined with anti-viral therapy, for the improved treatment of chronic hepatitis C virus (HCV) infection and related conditions, including liver function. The compositions, kits and uses of the invention, as compared to the use of SOC therapy alone: improves the rate of early response to therapy as measured by early virologic markers (e.g., RVR and EVR), enlarges the pool of patients who will have sustained responses to therapy over the long term, offers shortened courses of therapy for certain patients, enables “rescue” of patients who are non-responders or intolerant to SOC therapy, improves liver function and / or reduces liver damage in patients, and enables the personalization of HCV therapy for a patient, which can result in dose sparing, improved patient compliance, reduced side effects, and improved long term therapeutic outcomes.

Disclosed are methods for the use of therapeutic polypeptide-encoding polynucleotides in the creation of transformed host cells and transgenic animals is disclosed. In particular, the use of recombinant adeno-associated viral (rAAV) vector compositions comprising polynucleotide sequences that express one or more mammalian PEDF or anti-angiogenesis polypeptides is described. In particular, the invention provides gene therapy methods for the prevention, long-term treatment and / or amelioration of symptoms of a variety of conditions and disorders in a mammalian eye, including, for example blindness, loss of vision, retinal degeneration, macular degeneration, and related disorders resulting from retinal or choroidal neovascularization in affected individuals.

Low dose pharmaceutical dosage form comprising nimesulide or its pharmaceutically acceptable salts, esters, solvates or hydrates thereof, along with one or more pharmaceutically acceptable excipient(s) are provided. The present invention also provides process of preparing such dosage forms and therapeutic methods of using such dosage forms. The low dose compositions 10 are designed to exhibit such bioavailability, which is effective in the treatment of NSAID indicated disorders particularly, which require long-term treatment regimens such as arthritis. Such compositions reduce the cost of therapy in diseases, which require long-term therapies, are easy to manufacture, and also result in the reduction of dose related side effects associated with nimesulide therapy.

In brachytherapy where position information relating to a radiation source is to be generated, a guidance system is adapted to acquire and process position data or position and tissue data, so that high-precision interventional radiotherapy can be carried out, especially according to a dose plan and for intra-fraction monitoring for a therapy plan or adaptive re-planning. The data can be stored and used to refine future treatment plans and for future correlation with long-term treatment outcome, especially in context with low energy brachytherapy.

A medical management system. The burdensome task of medication logging is greatly reduced for a patient when compared to conventional methods to perform these tasks. Moreover, the invention allows for pharmaceutical supplier / providers and healthcare providers the ability better to manage, track, and trend the medication and products that must be provided to patients. This integrated ability allows for better management of the inventory of highly perishable and life-saving medications for chronically ill patients. The invention also allows for highly accurate communication between patients and other parties including his / her medical doctor, a pharmaceutical supplier / provider who provides medications and products for the patient, as well as the insurance provider providing medical insurance coverage for the patient. The system integrates embedded functionality that ensures that in the accidental event that a patient is prescribed tainted medication, the patient is warned of the taint in due time before self-administering the medication to avoid potentially contracting a disease or other ailment from the tainted medication. Patient medication is tracked and trending over the lifetime of the medication and the treatment period for the patient. Exceptions that outlay the trending of the patient's medication are identified and properly communicated, sometimes automatically, to a healthcare provider or medical doctor who treats the patient. The system is adaptable for use generally or to treat specific diseases, such as chronic diseases as hemophilia, diabetes, asthma, HIV, and other diseases requiring long term treatment and ongoing administration of medications and products.

The invention provides a sterilizing method of a spherical phaeocystis culture solution, and relates to a microalgae culture solution. The method comprises the following steps: centrifuging algae solution which grows to an exponential phase, and removing supernatant; carrying out gravity suspension on algae cells with an f / 2 culture medium, centrifuging, and removing supernatant, repeating twice, and carrying out gravity suspension on the algae cells with the f / 2 culture medium; adding SDS (sodium dodecyl sulfate) and antibiotics, wherein the antibiotics are clindamycin, azithromycin, gentamicin, kanamycin, streptomycin, cefotaxime, ampicillin and rifamycin; culturing under illumination, centrifuging the algae solution and removing supernatant during culturing, carrying out gravity suspension on the algae cells with the f / 2 culture medium, centrifuging and removing supernatant, removing residual SDS and the antibiotics, transferring into the f / 2 culture medium, and culturing under illumination; and selecting survival transferred algae solution which is treated with SDS and the antibiotics, and detecting whether bacteria exist or not after the transferred algae solution grows to the exponential phase. The method is convenient to operate, complex operations, such as bacterium separation and test on sensitivity to antibiotics and the like, are avoided, and long-term treatment of high-concentration antibiotics has good sterilization effect.

The invention discloses an anti-hypelipidemic powder mainly for diabetes patient and the preparing method. The raw material essentially comprises balsam pear powder, union powder, black soybean powder, duck wheat powder and pumpkin powder. The early stage curative effect of this product is apparent and the medium-long term curative effect is stable.

The invention discloses guanidine hydrochloride sustained release preparation and a preparation method thereof. The guanidine hydrochloride sustained release preparation is mainly prepared by guanidine hydrochloride, a filling agent, sustained release materials and potential of hydrogen (pH) sensitive materials. The preparation method comprises the steps of firstly preparing all raw materials according to proportion, evenly mixing the guanidine hydrochloride, the filling agent, the sustained release materials and the pH sensitive materials at high speed, granulating and drying the evenly mixed powder, finally adding a flow agent, a lubrication agent and an adhesion agent, tableting according to a general method, and achieving guanidine hydrochloride sustained release tablets. The guanidine hydrochloride sustained release preparation is small in side effect, obviously reduces difference of preparation of different batches, improves stability of samples, is convenient long term curing of patients and improves compliance of medicine. A patient can take the guanidine hydrochloride sustained release tablets once a day, so that effective drug concentration in bodies can be guaranteed for 24 hours, and nervous centralis side reactions caused by the fact that a blood concentration peak value is high due to general preparation is reduced.

The invention discloses a device and a method for dehydrating heavy sump oil, which belongs to the technical field of petrochemical wastewater treatment. The method has the characterized by comprising the following steps of leading out sump oil in a tank area and entering the sump oil into a Y-shaped filter; filtering, boosting via a booster pump, and then entering the sump oil into a steam heat exchanger (1), and heating to 80-130 DEG C; then introducing the sump oil in a vortex dehydrator (2), and separating the sump oil into a low-water-content sump oil phase and a low-oil-content sewage phase, and entering the low-water-content sump oil phase into a coalescence dehydrator (4), further dehydrating to obtain low-water-content oil, and leading the low-water-content oil out of the device, and meanwhile, entering the low-oil-content sewage phase into a vortex oil remover (3), separating the low-oil-content sewage phase into a high-water-content sump oil phase and a sewage phase, discharging the sewage phase, and cyclically performing a dehydration treatment on the high-water-content sump oil phase. According to the device and the method, the continuous performance of dehydration for heavy sump oil is realized, deep dehydration and deep oil removal are performed simultaneously, and non-thorough parts can be cyclically dehydrated and separated; the device and the method are low in energy consumption, convenient to operate, high in dehydration rate, strong in adaptability to heavy sump oil with various water contents and dirt contents, and suitable for performing a long-term treatment on a large amount of heavy sump oil.

This invention is directed to a method of treating drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with noribogaine or a pharmaceutically acceptable salt and / or solvate thereof at a dosage that provides a therapeutic serum concentration. In one embodiment, the average serum concentration is 50 ng / mL to 180 ng / mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds, and preferably about 30 milliseconds.

The invention relates to a stabilization treatment method for heavy metal, in particular to a P-alkalinity displaying stabilization treatment method for heavy metal containing heavy metal dust. Alkaline reagents and heavy metal fixing agents are added and mixed. The invention provides a stable and long-term treatment method for heavy metal containing heavy metal dust; in a test method of an acetic acid buffer solution method according to a People's Republic of China (PRC) HJT 300-2007 solid waste leaching toxicity leaching method, a standard value of household refuse landfill pollution control standard GB16889-2008 can be stably reached, the cost is low, and the environmental load can be lightened.

The invention discloses a loess platform landslip comprehensive treatment method based on underground water level control. The method is characterized in that a method combining the long term and the medium and short term is adopted; a long term treatment method includes the step that the unfavorable situation that the underground water level rises continuously is restrained based on a water-saving irrigation initiative prevention and control measure, and therefore a landslip risk is controlled; and a medium and short term treatment method includes the step that the existing ultra-high underground water level fast lowers through an effective drainage engineering measure, and the purpose of reducing landslip hazards is achieved. The loess platform landslip comprehensive treatment method has the beneficial effects that by means of the technical scheme, both symptoms and root causes of landslips can be treated, on the long term scale, the unfavorable situation that the underground water level rises continuously is restrained based on the water-saving irrigation initiative prevention and control measure, and therefore the landslip risk is controlled; and on the medium and short term scale, the existing ultra-high underground water level fast lowers through the effective drainage engineering measure, and the purpose of reducing the hazards is achieved.

The invention discloses an efficient artificial ventilator for cardiological nursing, comprising a medical mask and a patient mask connected with each other through a gas conducting tube; the gas conducting tube comprises an upper gas conducting tube and a lower gas conducting tube; the connection of the upper gas conducting tube and the medical mask is provided with a first intake port, the connection of the lower gas conducting tube and the patient mask is provided with a second intake port, the patient mask is provided with a nasal auto-blocking structure, the upper gas conducting tube is provided with a liquid blocking preventive structure, and the lower gas conducting tube is connected with an auxiliary artificial ventilation structure. The efficient artificial ventilator for cardiological nursing allows the nasal cavity of a patient to be automatically blocked during artificial ventilation so that artificial ventilation is more effective; it can be prevented that liquid exhaled by medical staff blocks a line; artificial ventilation and auxiliary artificial ventilation can be carried out alternately; therefore, artificial ventilation frequency can be kept constantly normal during long-term treatment of a patient, and therapy of the patient is benefited.

This invention pertains to a therapeutic pressure applicator with a sensor and transceiver worn by a patient during daily activity to apply pressure to a specific body part during long term treatment, and used in a system with a device such as a cell phone to receive and display real-time pressure data to alert the patient and physician when the pressure is outside a desired range. The applicator includes a securement member and a pressure adjusting device with a pressure adjusting dial, pressure sensing component, pressure focusing plate and cushion. Rotating the dial retracts or extends the sensing component, focusing plate and cushion. The applicator has a computer module with a CPU, memory, transceiver, power source and a force sensor. The focusing plate aligns a pressure button into pressed engagement with the sensor to transmit real-time focused pressure data to the CPU, which converts the focused data into real-time cushion pressure data. The transceiver periodically communicates the long-term, real-time cushion pressure data to the cell phone that displays and stores the data.

The invention relates to a method for preparing a high-air-permeability water-absorbing backing paper for sanitary products. Coniferous wood pulp is used as long-fiber raw material, hardwood pulp is used as short-fiber raw material, and they are beaten separately. Processing, mixing according to the long-fiber raw material accounting for 85wt%, the mixed pulp is not processed by a refiner, and after entering the pressure screen to remove slag, it enters the pulp tank, and then after being formed, pressed and dried by a paper machine, it is wrinkled. Get high air permeability absorbent backing paper for hygiene products. Compared with the prior art, the preparation process of the present invention does not add wet strength agent and carboxymethyl cellulose, and the prepared product has good air permeability, high strength, safety, sanitation and environmental protection.

The invention provides a portable cervical and lumbar vertebra disease ultrasonic therapy instrument, comprising an ultrasonic seat, an ultrasonic generator, an electric pulse generator, a central controller and a mobile controller. The outer surface of the ultrasonic seat is provided with a tablet cavity, which has a metal sheet stamping structure and is a rectangular or circular groove. The ultrasonic generator is arranged in close contact with the tablet chamber and outside the bottom surface of the tablet chamber. The electric pulse generator is electrically connected to the tablet chamber. The central controller comprises a circuit board, a far-infrared receiver, a bluetooth module, a WiFi module and a storage battery. The mobile controller is wirelessly connected with the central controller through the far-infrared receiver, the bluetooth module or the WiFi module. The central controller is electrically connected to the ultrasonic generator and the electric pulse generator. The invention has the beneficial technical effects that medicine, ultrasonic wave and electric pulse are adopted for the purpose of collaborative treatment, tablets are close to a pain site and the curative effect is remarkable; the portable cervical and lumbar vertebra disease ultrasonic therapy instrument has a portable structure and makes it easy for patients to adhere to long-term treatment.

A method for treating mammalian articular cartilage disorders, more particularly osteoarthritis, and trauma-related cartilage injuries using insulin-like growth factor I (IGF-I) is provided. The method comprises increasing the amount of IGF-I at the diseased or injured articular site to a therapeutically effective level that is capable of maintenance and / or regeneration of cartilage, which is beneficial to the long-term treatment of osteoarthritis and trauma-related injuries to cartilage tissues. In one embodiment of the invention, single doses of at least 0.01 mg of pharmaceutically effective IGF-I are administered intermittently such that the duration of time off of therapy is greater than the time on therapy, more preferably with a frequency of administration of about once per week or less.

The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin reuptake inhibitor (NSRI) to a patient with FMS.

The invention discloses a florfenicol compound composition and a preparation method thereof. The composition is composed of florfenicol, azithromycin, tylosin, propylene glycol, dimethyl formamide, alpha-pyrrolidone, anhydrous ethanol and polyvinylpyrrolidone (PVP). The preparation method of the composition comprises steps of: 1) adding dimethyl formamide to florfenicol, stirring and dissolving; and sequentially adding propylene glycol, alpha-pyrrolidone and anhydrous ethanol, and stirring to mix evenly; 2) adding azithromycin and tylosin, and stirring to mix evenly; 3) heating with stirring at 40 DEG C, adding polyethylene pyrrole pyrrolidone, dissolving and continuing to stir for 15min; and 4) filtering the obtained solution, inflating nitrogen and encapsulating to obtain the florfenicol compound composition. The compound composition provided by the invention is mainly used in the treatment of swine respiratory diseases, and especially has specific long-term treatment effect and no recurrence on respiratory diseases, such as infectious pleuropneumonia, Haemophilus parasuis, swine plague and asthma.

The invention provides compounds, pharmaceutical compositions and methods of use of certain compounds that are antagonists of the chemokine CXCR4 receptor for the treatment of proliferative conditions mediated by CXCR4 receptors or for the treatment of viral infections. The compounds provided interfere with the binding of SDF 1 to the receptor. These compounds are particularly useful for treating or reducing the severity of hyperproliferative diseases by inhibiting metastasis, or for reducing entry of HIV in to a cell while not reducing the capacity of the stem cells to proliferate. The compounds may be useful for long term treatment regimes.